Discover
DRMA
Dermata Therapeutics, Inc.
1.38
2 x 1.01
2 x 1.65
bid
ask
+
0.09
6.98%
2 @ 04:00 PM
1.37 -0.01 (0.72%)
| Ytd | -40.52% | |
| 1y | -78.47% |
1.28
day range
1.41
1.10
52 week range
8.00
| Open | 1.29 | Prev Close | 1.29 | Low | 1.28 | High | 1.41 | Mkt Cap | 5.55M |
| Vol | 178.13K | Avg Vol | 74.82K | EPS | -4.17 | P/E | N/A | Forward P/E | -0.32 |
| Beta | 0.79 | Short Ratio | 0.52 | Inst. Own | 0.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 1.26 | 200-d Avg | 2.27 | 1yr Est | 6.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | 0 | -2.04 | N/A | N/A |
| 2024-08-07 | 2024-06 | 0 | -4.18 | N/A | N/A |
| 2024-05-15 | 2024-03 | 0 | -7.05 | N/A | N/A |
| 2024-03-21 | 2023-12 | 0 | -3.15 | N/A | N/A |
| 2023-11-09 | 2023-09 | 0 | -8.1 | N/A | N/A |
| 2023-08-10 | 2023-06 | 0 | -9.45 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-21 | Maxim Group | Upgrade | Buy | Buy |
| 2023-03-23 | Maxim Group | Upgrade | Buy |
Profile
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Tower Research Capital LLC (TRC) | 2.89K | 3.56K | 0.14% |
| 2024-09-29 | Wells Fargo & Company | 2.05K | 2.52K | 0.10% |
| 2024-09-29 | UBS Group AG | 1.50K | 1.84K | 0.07% |
| 2024-09-29 | Bank of America Corporation | 10.00 | 12.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 6.58K | 8.10K | 0.32% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 1.83K | 2.25K | 0.09% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2025-08-01 |
| 1 : 15 | 2024-05-16 |
| 1 : 16 | 2023-03-14 |